AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Tuesday 17 November 2026
News from the 24 hours to Tuesday morning, 17 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was led by a string of regulatory successes, chiefly US and EU clearance for Klygefa, the myasthenia gravis treatment, US clearance for Imfinzi in bladder cancer and a European recommendation for the blood pressure drug Baxfendy. Smaller counterweights were reported US job cuts, a regulator's rejection of a partner's cancer drug and a busy myasthenia market.
What drove it
- Klygefa approvals
- Imfinzi bladder cancer approval
- Baxfendy EU recommendation
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 11 Nov | +6.3 | 22 |
| Thu 12 Nov | +7.5 | 25 |
| Fri 13 Nov | +5.3 | 8 |
| Sat 14 Nov | +5.5 | 39 |
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
| Tue 17 Nov | +9.7 | 45 |
| Wed 18 Nov | +7.0 | 29 |
13 stories · 45 headlines · strongest first
Pharma and healthcare on 17 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca's Klygefa approved for myasthenia gravis in US and EU +10.016 headlines today · 19 in all, since 15 November · Outlets report Klygefa has won EU approval alongside its US approval for generalised myasthenia gravis. | ||
| +10.0 | Two US regulatory clearances for new uses and a new drug. | |
| +10.0 | New drug cleared in both US and Europe. | |
| +10.0 | Next-generation therapy cleared in both markets. | |
| +10.0 | American regulator clears new generalised myasthenia treatment. | |
| +10.0 | Rare muscle disorder drug cleared in two regions. | |
| +10.0 | Self-administered therapy cleared in US and Europe. | |
| +10.0 | European clearance for myasthenia treatment. | |
| +10.0 | Approvals secured on both sides of Atlantic. | |
| +10.0 | European clearance for myasthenia drug. | |
| +10.0 | US clearance for myasthenia treatment. | |
| +10.0 | Adult myasthenia drug cleared in Europe. | |
| +10.0 | European clearance for myasthenia treatment. | |
| +10.0 | Transatlantic approvals for new drug lift outlook. | |
| +10.0 | US and European clearance for autoimmune treatment. | |
| +8.3 | Part of roundup noting approvals for its myasthenia asset. | |
| +5.0 | Approval positive, but competition in the field is heavy. | |
| FDA approves Imfinzi regimen for bladder cancer +10.06 headlines today · 15 in all, since 14 November · Coverage reports US approval of Imfinzi with chemotherapy for cisplatin-ineligible muscle-invasive bladder cancer. | ||
| +10.0 | US clearance for broader use of cancer drug and new therapy. | |
| +10.0 | US clearance for bladder cancer combination. | |
| +10.0 | US clearance for bladder cancer combination. | |
| +10.0 | Company announcement of US bladder cancer clearance. | |
| +10.0 | Two drugs cleared in US. | |
| +10.0 | US clearance for bladder cancer regimen. | |
| EU committee recommends AstraZeneca's Baxfendy for hypertension +8.66 headlines today · 14 in all, since 14 November · Reports cover the EU panel's recommendation of Baxfendy for uncontrolled hypertension. | ||
| +8.3 | Positive European recommendation backed by late-stage trials. | |
| +8.3 | European committee backing following US clearance. | |
| +8.3 | Blood pressure drug backed for European clearance. | |
| +8.3 | European committee supports hypertension drug. | |
| +8.3 | European panel backs blood pressure medicine. | |
| +8.3 | European support for hypertension drug. | |
| AstraZeneca wins several regulatory approvals +9.35 headlines today · 8 in all · Round-ups cover several AstraZeneca approvals spanning rare disease, bladder cancer and blood pressure. | ||
| +10.0 | Four regulatory successes across several areas. | |
| +10.0 | Several approvals covering bladder cancer and a rare disease. | |
| +9.2 | Briefing highlights its regulatory successes. | |
| +9.2 | Progress across three treatment areas. | |
| +6.7 | General positive coverage of new medicines progress. | |
| AstraZeneca unit defeats Soliris monopolisation suit +8.32 headlines today · 4 in all · A lawsuit by an insurer alleging Soliris monopolisation was defeated. | ||
| +8.3 | Company avoids litigation over alleged market dominance of a drug. | |
| +8.3 | Subsidiary wins dismissal of insurer's competition claim. | |
| AstraZeneca expands Karolinska obesity research partnership +5.02 headlines today · AstraZeneca is putting SEK 30 million towards obesity studies at Karolinska Institutet. | ||
| +5.0 | Research partnership broadened to cover obesity. | |
| +5.0 | Funding for obesity research at Swedish institute. | |
| AstraZeneca reduces its US sales workforce by 600 positions −3.02 headlines today · 21 in all, since 14 November · Reports say AstraZeneca is cutting 600 US commercial jobs as part of a savings plan. | ||
| −4.2 | Reported US job cuts. | |
| −3.3 | Sales staff reductions as part of cost savings drive. | |
| Ultomiris kidney result for AstraZeneca +7.91 headline today · 2 in all, since 13 November · The UAE conditionally approved Ultomiris for IgA nephropathy. | ||
| +7.5 | First conditional approval in UAE for kidney disease use. | |
| FDA declines Summit cancer drug AstraZeneca backed −6.71 headline today · Barron's reports the FDA did not yet approve a cancer drug from Summit, in which AstraZeneca had invested. | ||
| −6.7 | Regulator rejected partner's cancer drug after big investment. | |
| AstraZeneca reportedly eyeing $10bn deal +1.71 headline today · Investors' Chronicle discusses why AstraZeneca is considering a $10bn deal. | ||
| +1.7 | Possible large acquisition under consideration. | |
| AstraZeneca Italy launches cancer narrative campaign +1.71 headline today · AstraZeneca Italy's head discussed a new cancer awareness narrative. | ||
| +1.7 | Local awareness campaign comments from Italian unit. | |
| AstraZeneca shares trade near resistance 0.01 headline today · A technical piece describes range-bound trading near a resistance level. | ||
| 0.0 | Technical analysis showing sideways share trading. | |
| AstraZeneca lobbying spend disclosed 0.01 headline today · A lobbying filing of $1.51 million was disclosed. | ||
| 0.0 | Routine disclosure of lobbying spend. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.